Search Results 601-610 of 18370 for alopecia

1. Addison's disease - Symptoms and causes - Mayo Clinic

   Learn about this rare but serious condition of the adrenal glands that's treated by replacing hormones the body needs.

2. Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma - Mayo Clinic

   ... alopecia and fatigue. Total bilirubin =< 1.5 x the upper limits of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ...

3. Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma - Mayo Clinic

   ... alopecia, fatigue. For patients enrolling on Cohort A or Cohort B: For patients treated with surgery, an interval of >= 21 days must have elapsed prior to ...

4. Ingrown hair - Symptoms and causes - Mayo Clinic

   Learn about causes, treatment and prevention of this common, painful skin condition — sometimes called razor bumps, barber's itch, shave bumps and ...

5. Phase 1/2 Study Of MRTX1719 In Solid Tumors With MTAP Deletion - Mayo Clinic

   - Recovery from the adverse effects of prior therapy at the time of enrollment to baseline or ≤ Grade 1 (excluding alopecia, peripheral neuropathy, and ...

6. A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial - Mayo Clinic

   Patient must have recovered from any adverse events due to prior anti-cancer therapy (i.e., have no residual toxicities > grade 1 with the exception of alopecia ...

7. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation - Mayo Clinic

   (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor), ...

8. Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Mayo Clinic

   All acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1 prior to study entry.

9. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia). Uncontrolled intercurrent ...

10. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

    0], with the exception of persistent alopecia, adrenal insufficiency, and hypothyroidism) due to prior treatment. Active pneumonitis, history of pneumonitis ...